Role Of Hiv Disease In The Pathogenesis Of Hepatitis B

艾滋病毒疾病在乙型肝炎发病机制中的作用

• 批准号: 6507015
• 负责人: Anthony S. Fauci
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6507015
• 关键词: AIDS therapy; HIV infections; adefovir; comorbidity; drug resistance; hepatitis B; hepatitis B virus group; human immunodeficiency virus; human subject; human therapy evaluation; lamivudine; liver cirrhosis; pathologic process; patient oriented research; tissue /cell culture; virus load

HIV related opportunistic infections have declined significantly as a result of anti-retroviral therapy. However, other serious medical diseases, such as advanced liver disease, have become an important area of concern in the clinical care of HIV-infected individuals. In this regard, HIV infection is thought to have a negative impact on the progression of liver disease as a result of chronic hepatitis B virus (HBV) infection. Unfortunately, many individuals with HBV disease fail first-line therapy with lamivudine. Adefovir dipivoxil may offer a therapeutic option to HIV- infected individuals who are co-infected with HBV who have failed lamivudine therapy. LIR investigators have recently opened two clinical trials assessing the safety and efficacy of low-dose adefovir (10 mg daily) for the treatment of chronic hepatitis B in HIV-infected individuals who have HBV-related liver disease and persistent HBV plasma viremia despite lamivudine therapy. In addition to evaluating the clinical safety and efficacy of adefovir, we are investigating the impact of HIV infection on HBV-specific cellular immune function. These studies will expand our understanding of the pathogenesis and treatment of HBV disease in HIV-infected people.

由于抗逆转录病毒疗法，与HIV相关的机会感染显着下降。但是，其他严重的医学疾病，例如晚期肝病，已成为艾滋病毒感染者临床护理的重要领域。在这方面，由于慢性乙型肝炎病毒（HBV）感染，HIV感染被认为对肝病的进展产生负面影响。不幸的是，许多HBV疾病的人无法通过拉米夫定治疗一线治疗。 Adefovir Dipivoxil可能会为与Lamivudine治疗失败的HBV感染的受HIV感染的个体提供治疗选择。 LIR研究人员最近开设了两项临床试验，评估了低剂量adefovir（每天10 mg）在患有HBV相关的肝脏疾病的HIV感染个体中治疗慢性丙型肝炎的安全性和功效，尽管具有HBV相关的肝脏疾病，并且尽管具有lamivudine疗法，但患有HBV相关的HBV血浆病毒。除了评估Adefovir的临床安全性和功效外，我们还研究了HIV感染对HBV特异性细胞免疫功能的影响。这些研究将扩展我们对感染HIV的人中HBV疾病的发病机理和治疗的理解。